Mark Breidenbach
Stock Analyst at Oppenheimer
(1.63)
# 3,439
Out of 5,129 analysts
48
Total ratings
30.91%
Success rate
0.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.65 | +324.24% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $16.11 | +86.22% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $13.09 | +625.74% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $5.05 | +395.05% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.32 | +3,008.49% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $14.09 | +1,603.34% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.95 | +5,323.73% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.71 | +309.36% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.59 | +1,912.58% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.60 | +476.92% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.90 | +1,083,233.33% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.65
Upside: +324.24%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $16.11
Upside: +86.22%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $13.09
Upside: +625.74%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $5.05
Upside: +395.05%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.32
Upside: +3,008.49%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $14.09
Upside: +1,603.34%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.95
Upside: +5,323.73%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.71
Upside: +309.36%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.59
Upside: +1,912.58%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.60
Upside: +476.92%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.90
Upside: +1,083,233.33%